These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 10443885)

  • 1. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
    Li DK; Paty DW
    Ann Neurol; 1999 Aug; 46(2):197-206. PubMed ID: 10443885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.
    Neurology; 1999 Sep; 53(4):679-86. PubMed ID: 10489026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
    Li DK; Zhao GJ; Paty DW;
    Neurology; 2001 Jun; 56(11):1505-13. PubMed ID: 11402107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
    Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
    Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Millefiorini E; Galgani S; Buttinelli C; Perciaccante G; Piazza G; Bozzao L; Fieschi C
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH
    Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].
    Boyko AN; Bakhtiyarova KZ; Boyko OV; Dudin VA; Zaslavskii LG; Malkova NA; Parshina EV; Poverennova IY; Sivertseva SA; Totolyan NA; Shchur SG; Khabirov FA; Goncharova ZA; Zakharova MN; Bolsun DD; Zinkina-Orikhan AV; Lin'kova YN; Chernovskaya TV; Porozova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(2):52-59. PubMed ID: 36843459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves.
    Liu C; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):451-6. PubMed ID: 10486390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.